5-year survey of methotrexate, cyclophosphamide (Endoxan), and vincristine (MEV) therapy for advanced non-Hodgkin's lymphomas

F. Lauria, M. Baccarani, M. Fiacchini, R. Frezza, M. Gobbi, S. Tura

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

5 courses of a combination chemotherapy regimen with methotrexate, cyclophosphamide (Endoxan), and vincristine were given to 64 patients, 37 with lymphocytic lymphoma (LL) and 27 with histiocytic lymphoma (HL). 18 of the 37 patients with LL (48%) achieved a complete remission (CR); 12 of these 18 patients have been in CR for 20-58 mth. Among the complete responders only 2 died. 22 of the 27 patients with HL (81%) achieved CR and 12 of these patients are still in CR. 10 of the complete responders have been relapse-free for 24-70 mth and 5 have been relapse-free for >60 mth. Clinical and hematologic tolerance was such that the interval between each course had to be prolonged in only 3 of the 64 patients and, with the exception of vincristine, the dosages were not reduced.

Original languageEnglish
Pages (from-to)1193-1197
Number of pages5
JournalCancer Treatment Reports
Volume62
Issue number8
Publication statusPublished - 1978

Fingerprint

Vincristine
Methotrexate
Non-Hodgkin's Lymphoma
Cyclophosphamide
Lymphoma, Large B-Cell, Diffuse
B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Recurrence
Combination Drug Therapy
Surveys and Questionnaires

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

5-year survey of methotrexate, cyclophosphamide (Endoxan), and vincristine (MEV) therapy for advanced non-Hodgkin's lymphomas. / Lauria, F.; Baccarani, M.; Fiacchini, M.; Frezza, R.; Gobbi, M.; Tura, S.

In: Cancer Treatment Reports, Vol. 62, No. 8, 1978, p. 1193-1197.

Research output: Contribution to journalArticle

Lauria, F. ; Baccarani, M. ; Fiacchini, M. ; Frezza, R. ; Gobbi, M. ; Tura, S. / 5-year survey of methotrexate, cyclophosphamide (Endoxan), and vincristine (MEV) therapy for advanced non-Hodgkin's lymphomas. In: Cancer Treatment Reports. 1978 ; Vol. 62, No. 8. pp. 1193-1197.
@article{9958bb6e912a42708a5a018cc2f9218f,
title = "5-year survey of methotrexate, cyclophosphamide (Endoxan), and vincristine (MEV) therapy for advanced non-Hodgkin's lymphomas",
abstract = "5 courses of a combination chemotherapy regimen with methotrexate, cyclophosphamide (Endoxan), and vincristine were given to 64 patients, 37 with lymphocytic lymphoma (LL) and 27 with histiocytic lymphoma (HL). 18 of the 37 patients with LL (48{\%}) achieved a complete remission (CR); 12 of these 18 patients have been in CR for 20-58 mth. Among the complete responders only 2 died. 22 of the 27 patients with HL (81{\%}) achieved CR and 12 of these patients are still in CR. 10 of the complete responders have been relapse-free for 24-70 mth and 5 have been relapse-free for >60 mth. Clinical and hematologic tolerance was such that the interval between each course had to be prolonged in only 3 of the 64 patients and, with the exception of vincristine, the dosages were not reduced.",
author = "F. Lauria and M. Baccarani and M. Fiacchini and R. Frezza and M. Gobbi and S. Tura",
year = "1978",
language = "English",
volume = "62",
pages = "1193--1197",
journal = "Cancer Treatment Reports",
issn = "0361-5960",
publisher = "U.S. National Cancer Institute",
number = "8",

}

TY - JOUR

T1 - 5-year survey of methotrexate, cyclophosphamide (Endoxan), and vincristine (MEV) therapy for advanced non-Hodgkin's lymphomas

AU - Lauria, F.

AU - Baccarani, M.

AU - Fiacchini, M.

AU - Frezza, R.

AU - Gobbi, M.

AU - Tura, S.

PY - 1978

Y1 - 1978

N2 - 5 courses of a combination chemotherapy regimen with methotrexate, cyclophosphamide (Endoxan), and vincristine were given to 64 patients, 37 with lymphocytic lymphoma (LL) and 27 with histiocytic lymphoma (HL). 18 of the 37 patients with LL (48%) achieved a complete remission (CR); 12 of these 18 patients have been in CR for 20-58 mth. Among the complete responders only 2 died. 22 of the 27 patients with HL (81%) achieved CR and 12 of these patients are still in CR. 10 of the complete responders have been relapse-free for 24-70 mth and 5 have been relapse-free for >60 mth. Clinical and hematologic tolerance was such that the interval between each course had to be prolonged in only 3 of the 64 patients and, with the exception of vincristine, the dosages were not reduced.

AB - 5 courses of a combination chemotherapy regimen with methotrexate, cyclophosphamide (Endoxan), and vincristine were given to 64 patients, 37 with lymphocytic lymphoma (LL) and 27 with histiocytic lymphoma (HL). 18 of the 37 patients with LL (48%) achieved a complete remission (CR); 12 of these 18 patients have been in CR for 20-58 mth. Among the complete responders only 2 died. 22 of the 27 patients with HL (81%) achieved CR and 12 of these patients are still in CR. 10 of the complete responders have been relapse-free for 24-70 mth and 5 have been relapse-free for >60 mth. Clinical and hematologic tolerance was such that the interval between each course had to be prolonged in only 3 of the 64 patients and, with the exception of vincristine, the dosages were not reduced.

UR - http://www.scopus.com/inward/record.url?scp=0018123429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018123429&partnerID=8YFLogxK

M3 - Article

C2 - 688255

AN - SCOPUS:0018123429

VL - 62

SP - 1193

EP - 1197

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 8

ER -